Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

The USPTO granted Moberg Pharma a U.S. patent covering an improved dosing regimen for MOB-015, its topical drug for onychomycosis. The U.S. is the first jurisdiction to grant a patent related to the regimen; the provided article text gives no further details on commercial impact.